164 related articles for article (PubMed ID: 24172716)
21. Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia.
Fredj NB; Romdhane HB; Woillard JB; Chickaid M; Fadhel NB; Chadly Z; Chaabane A; Boughattas N; Aouam K
Int J Infect Dis; 2021 Mar; 104():562-567. PubMed ID: 33476758
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of isoniazid-induced hepatotoxicity in zebrafish larvae: Activation of ROS-mediated ERS, apoptosis and the Nrf2 pathway.
Jia ZL; Cen J; Wang JB; Zhang F; Xia Q; Wang X; Chen XQ; Wang RC; Hsiao CD; Liu KC; Zhang Y
Chemosphere; 2019 Jul; 227():541-550. PubMed ID: 31004821
[TBL] [Abstract][Full Text] [Related]
23. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
24. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
[TBL] [Abstract][Full Text] [Related]
25. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.
Parikh R; Dalwadi S; Aboti P; Patel L
J Antibiot (Tokyo); 2014 May; 67(5):387-94. PubMed ID: 24569669
[TBL] [Abstract][Full Text] [Related]
26. Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes.
Lee KK; Fujimoto K; Zhang C; Schwall CT; Alder NN; Pinkert CA; Krueger W; Rasmussen T; Boelsterli UA
Free Radic Biol Med; 2013 Dec; 65():584-594. PubMed ID: 23911619
[TBL] [Abstract][Full Text] [Related]
27. Isoniazid potentiation of a guinea pig model of halothane-associated hepatotoxicity.
Lind RC; Gandolfi AJ; Hall PM
J Appl Toxicol; 1990 Jun; 10(3):161-5. PubMed ID: 2380477
[TBL] [Abstract][Full Text] [Related]
28. Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver in Vivo.
Koen YM; Galeva NA; Metushi IG; Uetrecht J; Hanzlik RP
Chem Res Toxicol; 2016 Jun; 29(6):1064-72. PubMed ID: 27097313
[TBL] [Abstract][Full Text] [Related]
29. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits.
Sarich TC; Youssefi M; Zhou T; Adams SP; Wall RA; Wright JM
Arch Toxicol; 1996; 70(12):835-40. PubMed ID: 8911642
[TBL] [Abstract][Full Text] [Related]
30. Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs.
Liu L; Li X; Huang C; Bian Y; Liu X; Cao J; Qu W; Miao L
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):527-537. PubMed ID: 32436768
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles.
Bhandari R; Kaur IP
Int J Pharm; 2013 Jan; 441(1-2):202-12. PubMed ID: 23220081
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
Desta Z; Soukhova NV; Flockhart DA
Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
Decloedt EH; Mwansa-Kambafwile J; van der Walt JS; McIlleron H; Denti P; Smith P; Wiesner L; Rangaka M; Wilkinson RJ; Maartens G
Int J Tuberc Lung Dis; 2013 Mar; 17(3):333-5. PubMed ID: 23407222
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury.
Liu N; Liu J; Zheng B; Zeng X; Ye Z; Huang X; Liu W; Liu Y; Fang Q; Chen L; Rao T; Ouyang D
Biomed Pharmacother; 2023 Apr; 160():114400. PubMed ID: 36805186
[TBL] [Abstract][Full Text] [Related]
35. Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
He L; Guo Y; Deng Y; Li C; Zuo C; Peng W
Xenobiotica; 2017 Feb; 47(2):154-163. PubMed ID: 28118809
[TBL] [Abstract][Full Text] [Related]
36. Investigations on the Influence of Zidovudine in the Pharmacokinetics of Isoniazid and Its Hepatotoxic Metabolites in Rats.
Ramanathan R; Sivanesan K
J Pharm Pract; 2019 Feb; 32(1):9-18. PubMed ID: 29017426
[TBL] [Abstract][Full Text] [Related]
37. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
[TBL] [Abstract][Full Text] [Related]
38. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis.
Thee S; Detjen AA; Wahn U; Magdorf K
Scand J Infect Dis; 2010 Apr; 42(4):294-8. PubMed ID: 20100111
[TBL] [Abstract][Full Text] [Related]
39. Toxicity studies of highly bioavailable isoniazid loaded solid lipid nanoparticles as per Organisation for Economic Co-operation and Development (OECD) guidelines.
Bhandari R; Singh M; Jindal S; Kaur IP
Eur J Pharm Biopharm; 2021 Mar; 160():82-91. PubMed ID: 33503492
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.
Mann A; Pelz T; Rennert K; Mosig A; Decker M; Lupp A
Hum Cell; 2017 Oct; 30(4):267-278. PubMed ID: 28527127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
